Published in Blood Weekly, June 15th, 2006
Revenues for the first quarter of 2006 were $1.24 million, a 69% increase compared to first quarter 2005 revenues of $732,000. Net product sales for the first quarter increased 238% to $1.17 million compared to $346,000 for the first quarter of 2005. The first quarter 2006 net loss attributable to common stockholders was $1.94 million or $0.22 per share compared to a net loss attributable to common stockholders of $3.5 million or $0.50 per share for the first quarter of 2005.
The first quarter revenue growth was attributable to increased sales of the company's rapid HIV...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.